End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
291.5 TWD | -3.16% | +1.39% | +7.17% |
Summary
- The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.
Strengths
- Before interest, taxes, depreciation and amortization, the company's margins are particularly high.
- The group's activity appears highly profitable thanks to its outperforming net margins.
- Analysts covering this company mostly recommend stock overweighting or purchase.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- The average price target of analysts who are interested in the stock has been strongly revised upwards over the last four months.
Weaknesses
- The company's enterprise value to sales, at 4.59 times its current sales, is high.
- In relation to the value of its tangible assets, the company's valuation appears relatively high.
- The price targets of various analysts who make up the consensus differ significantly. This reflects different assessments and/or a difficulty in valuing the company.
Ratings chart - Surperformance
Sector: Pharmaceuticals
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
+7.17% | 2.47B | - | ||
+34.32% | 693B | C+ | ||
+29.39% | 584B | B | ||
-2.78% | 372B | C+ | ||
+20.59% | 332B | B- | ||
+6.71% | 294B | C+ | ||
+14.11% | 239B | B+ | ||
-3.03% | 211B | A+ | ||
+10.02% | 210B | B- | ||
+9.04% | 168B | C+ |
Financials
Valuation
Momentum
Consensus
Business Predictability
Technical analysis
- Stock Market
- Equities
- 1795 Stock
- Ratings Lotus Pharmaceutical Co., Ltd.